Company Info

TC Biopharm

Drug Discovery & Development

Overview

We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life.

TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Established in 2014, we have expanded into 5 global locations and have grown to over 100 employees.

2 Contributions1 / 1

Clinical Research

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

TC Biopharm

PR-10-24-NI-55Oct 22, 2024

Cell Therapy

Targeting Cancers by Leveraging the Biology of Gamma Delta T Cells

Bryan Kobel

TC Biopharm

PAO-07-022-CL-03Aug 09, 2022

1 / 1

1 Contributors1 / 1

Bryan Kobel

Chief Executive Officer

1 / 1